This application relates generally to the field of intraocular devices. More particularly, this application is directed to intraocular implants and lenses (IOLs) with an aperture to increase depth of focus (e.g., “masked” intraocular lenses), and methods of making the same.
The human eye functions to provide vision by transmitting and focusing light through a clear outer portion called the cornea, and further refining the focus of the image onto a retina by way of a crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the transparency of the cornea and the lens.
The optical power of the eye is determined by the optical power of the cornea and the crystalline lens. In a normal, healthy eye, sharp images of distant objects are formed on the retina (emmetropia). In many eyes, images of distant objects are either formed in front of the retina because the eye is abnormally long or the cornea is abnormally steep (myopia), or formed in back of the retina because the eye is abnormally short or the cornea is abnormally flat (hyperopia). The cornea also may be asymmetric or toric, resulting in an uncompensated cylindrical refractive error referred to as corneal astigmatism.
Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the crystalline lens can be removed and replaced with an intraocular lens (IOL). However, some intraocular lenses may still leave defects in a patient's non-distance eyesight.
Methods of manufacturing masked intraocular lenses can include a molding process. In general, the molding process can include pouring an uncured material into a mold and then curing the material with a combination of UV light and heat temperature cycles. However, when performing a molding process with both optically transmissive and opaque materials (e.g., an optically transmissive optic material and an opaque mask material), it can be difficult to produce precise border lines between the optic and the aperture, which can reduce the optical performance of the intraocular lens.
The present disclosure is generally related to methods of manufacturing a masked intraocular lens with an annular mask embedded within or positioned on an anterior or a posterior surface of the optic. The mask and the optic may comprise the same material, such as an acrylic copolymer or silicone. The methods disclosed herein produce a precise border line at the interface between inner and outer diameters of the mask and the optic.
The method of manufacturing the intraocular lens can include filling an annular mask-forming feature (e.g., a trough) with an opaque mask material, adding optically transmissive optic material over the opaque mask material; and fully curing the opaque mask material and the optically transmissive optic material to form a mask and an optic. The mask can be sufficiently thick to prevent transmission of at least 90% of incident visible light (or at least about 98% of incident visible light). The annular mask-forming feature can be provided in a lens mold or in a partially-formed optic.
Any feature, structure, or step disclosed herein can be replaced with or combined with any other feature, structure, or step disclosed herein, or omitted. Further, for purposes of summarizing the disclosure, certain aspects, advantages, and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No aspects of this disclosure are essential or indispensable.
Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. Furthermore, various features of different disclosed embodiments can be combined to form additional embodiments, which are part of this disclosure.
Patients who undergo intraocular lens (IOL) implantation surgery may still suffer from defects in their non-distance eyesight (e.g., presbyopia). One technique for treating such defects is by including an annular mask within or on the optic that increases the patient's depth of focus. The light rays that pass through the aperture in the mask converge at a focal point on the retina, while the light rays that would not converge at the focal point on the retina are blocked by an opaque portion of the mask configured to prevent at least some or substantially all visible light from being transmitted through the mask.
Mask
In some embodiments, the outer periphery of the mask 2034a is generally circular with an outer diameter of at least about 3 mm and less than about 6 mm. In some embodiments, the diameter of the outer periphery of the mask 2034a is at least about 3 mm and less than or equal to about 4 mm.
A thickness of the mask 2034a can be constant or can vary between the inner periphery (near the aperture) and the outer periphery. For example, the thickness may increase from an outer periphery and/or inner periphery of the mask 2034a and toward a radial midline of the annular region 2036a. In general, the thickness at any location of the mask 2034a can be less than or equal to about 200 microns, or less than or equal to about 100 microns, but preferably between about 1 micron and about 20 microns. For example, the thickness of the mask 2034a can be within the range: from about 1 micron to about 40 microns, from about 5 microns to about 20 microns, from about 5 microns to about 15 microns. In some implementations, the thickness of the mask 2034a can be within about two microns of: about 15 microns, about 10 microns, about 8 microns, or about 5 microns.
The aperture 2038a can transmit substantially all incident visible light along the optical axis 2039a. For example, the aperture 2038a can be a through-hole in the annular region 2036a or a substantially light transmissive (e.g., transparent to visible light) portion thereof. The aperture 2038a can be substantially circular and/or substantially centered around the optical axis 2039a of the mask 2034a. The size of the aperture 2038a can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2038a can be dependent on the location of the mask within the eye (e.g., distance from the retina). In some implementations, the aperture 2038a can have a diameter of at least about 0.85 mm and less than or equal to about 2.2 mm, at least about 1.1 mm and less than or equal to about 1.6 mm, or at least about 1.3 mm and less than or equal to about 1.4 mm.
The annular region 2036a can prevent transmission of substantially all or at least a portion of the spectrum of the incident visible light (e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye) and/or the spectrum of non-visible light (e.g., radiant energy outside the range visible to humans). Preventing transmission of visible light through the annular region 2036a can block light that would not converge at the retina and fovea to form a sharp image. In some implementations, the annular region 2036a can prevent transmission of at least about: 90 percent of incident visible light, 92 percent of incident visible light, 95 percent of incident visible light, 98 percent of all incident visible light, or 99 percent of all incident visible light. In other words, the annular region 2036a can transmit no more than about: 10 percent of incident visible light, 8 percent of incident visible light, 5 percent of incident visible light, 3 percent of incident visible light, 2 percent of incident visible light, or 1 percent of incident visible light.
In some embodiments, opacity of the annular region 2036a is achieved because the material used to make mask 2034a is naturally opaque. In other embodiments, the material used to make the mask 2034a may be naturally substantially clear but treated with a dye or other pigmentation agent (e.g., carbon black).
Further variations of masks can be found in U.S. Pat. No. 7,628,810, filed May 26, 2004, U.S. Publication No. 2012/0143325, filed Feb. 19, 2012, U.S. Publication No. 2011/0040376, filed Aug. 13, 2010; U.S. Publication No. 2013/0268071, filed Nov. 30, 2012; U.S. Publication No. 2014/0264981; U.S. Publication No. 2015/0073549, filed Aug. 7, 2014; U.S. Pat. No. 5,662,706, filed Jun. 14, 1996 U.S. Pat. No. 5,905,561, filed Jun. 14, 1996; and U.S. Pat. No. 5,965,330, filed Dec. 6, 1996, all of which are included in the Appendix.
Intraocular Lens
As shown in
The optic 1004 may be monofocal or multifocal and it can have positive or negative optical power. The optic 1004 may be aspheric or any other configuration as the context may dictate. In some implementations, the greatest thickness of the optic 1004 is at the center of the optic 1004. In other implementations, the optic 1004 may have a reduced thickness at its center, which is further described in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, and is included in the Appendix. The optic 1004 may be substantially circular with an outer diameter between about 5.0 mm and about 8.0 mm, such as about 6.0 mm. A central thickness of the optic 1004 can be less than or equal to about 1.0 mm, such as between about 0.75 mm and about 1.0 mm.
The intraocular lens 1000 may include one or more haptics 1008 (e.g., one, two, three, four, or more) to prevent the intraocular lens 1000 from moving or rotating within the eye. As used herein the term “haptic” is intended to be a broad term encompassing struts and other mechanical structures that can be opposed against an inner surface of an eye and mounted to an optic to securely position an intraocular lens in an optical path of an eye. The haptics 1008 can be a variety of shapes and sizes depending on the location the intraocular lens 1000 is implanted in the eye. The haptics 1008 may be C-shaped, J-shaped, plate design, or any other design. The haptics 1008 may be manufactured substantially flat or vaulted with respect to the optic. Variations on the shape of the optic and the haptics can be found in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is included in the Appendix.
The mask 1012 can be formed on an anterior surface 1016 of the optic 1004 (see
Methods of Manufacturing
In some embodiments, the optic 1004 can be formed by molding a liquid lens material, such as an acrylic or silicone material, and curing the material into a solid. A completed solid mask 1012 can be pre-manufactured (e.g., from a different material than the optic) and positioned on or in the optic as part of this molding process. However, in this type of process where the mask 1012 is pre-manufactured and then molded into the optic, there is a potential for an inadequate bond between the mask and the optic. In addition, if the mask and the optic are made of different materials, there is a potential that the optical performance of the intraocular lens can be compromised due to the mask and optic materials potentially having elasticities and/or thermal expansion properties, which are too dissimilar. For example, if the material properties of the optic 1004 and the mask 1012 are not adequately compatible, then deformations, such as those resulting from injection forces during surgical implantation or swelling that may occur during manufacture due to chemical extractions, may damage the intraocular lens. Similarly, temperature shifts that occur during manufacture and/or surgical implantation can also damage the intraocular lens.
It can therefore be advantageous to manufacture the intraocular lens using a process where the mask is molded from the same material as the optic (e.g., a liquid acrylic or silicone material) at the same general time and/or such that the mask and optic undergo similar curing sequences (e.g., the mask and optic can be at least partially cured together). For example, the mask can be formed from a liquid material that has been modified to be substantially opaque by mixing in a dark pigment dye or dark particles, whereas the optic can be formed from the unmodified transparent liquid material. In this type of manufacturing process, however, mixing, bleeding, and/or blending can occur between the opaque mask material and the transparent optic material. If this occurs, the outer and inner diameter borders of the mask can become blurred and/or diffuse. This can negatively impact the optical performance of the intraocular lens.
This mixing, bleeding, and/or blending of the opaque and transparent liquid materials can be reduced or prevented by providing a mask-forming feature in the lens mold which can help prevent the opaque material from spreading beyond the desired region where the mask is to be formed on the surface of the optic or within the optic. In some embodiments, the mask-forming feature can be an annular trough formed in the lens mold at the location where the mask is to be positioned. This mask-forming trough can have inner and outer diameters, which correspond to the desired size of the mask. The opaque material used to form the mask can be added to fill this trough. Transparent material used to form the optic can be added over or around the opaque material in the mask-forming trough. The trough can help to prevent the opaque material from mixing, bleeding, and/or blending with the transparent material in a way that would blur the outer or inner diameter of the mask. The trough can achieve this, for example, through surface tension, which helps to hold the opaque material in place. In this way, more precise mask borders can be achieved. For example, the inner border line of the mask (which defines the central circular aperture 2038) and the outer border line of the mask (which defines the outer circular perimeter of the mask 2034) can each be circular to within 100 microns (e.g., any location along the inner or outer border of the mask can be within 100 microns of a perfect circle [or within 75 microns, or within 50 microns, or within 25 microns]). In addition, the outer border and the inner border can be concentric to within ±200 microns (e.g., the outer border and the inner border at any given angular position can be within 200 microns of being perfectly concentric [or within 150 microns, or within 100 microns, or within 50 microns]).
When forming an intraocular lens with the mask positioned on an anterior or posterior surface of the optic, a lens forming surface of the lens mold can include a mask-forming feature located at a position where the mask is to be formed. The mask-forming feature can be generally annular and defined by an outer edge and an inner edge. These edges can be sharp knife edges in order to more effectively hold the opaque mask material in place via surface tension. The lens forming surface can also include an optic region positioned radially inward and/or outward of the mask-forming feature. As just mentioned, the mask-forming feature can be an annular trough. This trough can be etched, machined, or otherwise cut into the lens forming surface of the lens mold. The trough can have a minimum depth that creates a mask thickness which provides less than 5% light transmission (or less than 3% or less than 2%). In some embodiments, the depth of the trough can be at least about 4 microns, or between about 5 microns and about 10 microns. But the trough can be as deep as practically appropriate without causing dissimilar material property interactions between the mask material and the optic material, resulting in poor injection performance (e.g., a maximum trough depth of about 150 microns).
The optic region of the lens forming surface of the mold will generally be curved in order to provide the intraocular lens with refractive optical power. In such embodiments, the mask-forming feature can have a different radius of curvature than the optic region. This difference in radius of curvature can result in a trough in the lens forming surface to create the mask-forming feature and facilitate the creation of a precise border between the mask and the optic. The radius of curvature of the mask-forming feature can be between about 25% and about 50% of the radius of the optic region, such as between about 25% and 35%, between about 30% and about 40%, between about 35% and about 45%, between about 40% and about 50%, or otherwise. In some implementations, the radius of curvature of the mask-forming feature can be between about 30% and about 35% of the radius of the optic region, such as about 32%. In other embodiments, however, the mask-forming feature and the optic region can have the same radius of curvature, but can be separated by a stepped transition.
After filling the mask-forming feature, the mask can optionally be partially or fully cured using, for example, a combination of UV light and heat cycles (block 1052). Thereafter, the mold can be filled with an optically transmissive optic material, which may be the same as the mask material (e.g., acrylic or silicone), to over-mold the mask (block 1054). Finally, the mask material and the optic material can be fully cured-again, using a combination of UV light and heat cycles (block 1056).
In an alternative embodiment, the intraocular lens may be manufactured with the mask embedded within the optic. The method can include at least partially filling a first mold portion with an uncured optic material (block 1060). The first mold portion can be filled up to the depth where the mask is to be formed in the interior of the optic. In this way, the optic is initially only partially formed just to the thickness where the mask will be embedded in the completed optic. In this case, the first mold portion need not include a mask-forming feature. Instead, a second mold portion, which mates with the first mold portion, can include a structure that is the physical complement of the desired mask-forming feature. For example, the second mold portion can include an annular projection located where the mask is to be formed. The annular projection will form a trough in the partially-formed optic. As discussed further below, after at least partial curing of the optic material in the first mold portion, this trough in the partially-formed optic becomes the mask-forming feature and can be filled with opaque mask material.
After the first and second mold portions are mated together, the uncured transparent optic material can be partially or fully cured to form a trough in the interior surface of the partial optic (block 1062). The trough in the partial optic can be filled with an opaque mask material (block 1064). The opaque mask material can be prepared, for example, by mixing or impregnating an optically transmissive mask material (e.g., an acrylic copolymer or silicone) with a high density of carbon black particles or other black dye or pigments as needed to provide opaque properties (e.g., to permit no more than about 2% light transmission). A specific and precise volume of uncured opaque mask material can be dispensed (e.g., with a cannula) to exactly fill the trough in the partial optic and define an outer diameter and an inner diameter of the annular mask. By relying on surface tension and capillary action of the viscous mask material, the dispensed volume can be specifically controlled to conform to the outer and inner edges of the trough in the partial optic. The exposed surface of the uncured mask material (i.e., opposite interior surface of the optic) can exhibit a curvature. After filling the trough in the partial optic, the mask can optionally be partially or fully cured (block 1066). Thereafter, the mold can be filled with additional optic material to over-mold the mask (block 1068). A third mold portion can be used in place of the second mold portion to form an outer surface of the optic. Finally, the mask material and the optic material can be fully cured (block 1070). In some implementations, one of the mold portions may include a protruding pin that defines the inner diameter of the mask-forming feature and radially centers the mask in the optic.
An alternative method of manufacturing an intraocular lens with an embedded mask is illustrated in
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.
The terms “approximately.” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately,” “about,” and “substantially” may refer to an amount that is within less than 10% of the stated amount, as the context may dictate.
The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 3 mm” includes “3 mm.”
Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the methods and IOLs shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the actions of the disclosed processes and methods may be modified in any manner, including by reordering actions and/or inserting additional actions and/or deleting actions. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the claims and their full scope of equivalents.
This application is continuation of U.S. patent application Ser. No. 15/765,611, filed on Apr. 3, 2018 which is a national stage application based on International Application No. PCT/US2016/055207, filed Oct. 3, 2016, which claims priority benefit of U.S. Patent Application No. 62/237,429, filed Oct. 5, 2015, which is hereby incorporated by reference in its entirety herein.
Number | Name | Date | Kind |
---|---|---|---|
2350421 | Schoder et al. | Jun 1944 | A |
2470927 | Hale, Jr. | May 1949 | A |
3034403 | Neefe | May 1962 | A |
3270099 | Camp | Aug 1966 | A |
3458870 | Stone | Aug 1969 | A |
3578850 | Grant | May 1971 | A |
3776230 | Neefe | Dec 1973 | A |
3794414 | Wesley | Feb 1974 | A |
3877502 | Hunckler | Apr 1975 | A |
3996627 | Deeg et al. | Dec 1976 | A |
4010496 | Neefe | Mar 1977 | A |
4104338 | Guerrieri | Aug 1978 | A |
4116439 | Chavarria et al. | Sep 1978 | A |
4210391 | Cohen | Jul 1980 | A |
4298996 | Barnet | Nov 1981 | A |
4340283 | Cohen | Jul 1982 | A |
4402579 | Poler | Sep 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4435050 | Poler | Mar 1984 | A |
4450593 | Poler | May 1984 | A |
4470159 | Peyman | Sep 1984 | A |
4505855 | Bruns et al. | Mar 1985 | A |
4512039 | Lieberman | Apr 1985 | A |
4563565 | Kampfer et al. | Jan 1986 | A |
4575373 | Johnson | Mar 1986 | A |
4596578 | Kelman | Jun 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4639105 | Neefe | Jan 1987 | A |
4646720 | Peyman et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4665913 | Esperance, Jr. | May 1987 | A |
4669466 | L'Esperance | Jun 1987 | A |
4669834 | Richter | Jun 1987 | A |
4676790 | Kern | Jun 1987 | A |
4676791 | LeMaster et al. | Jun 1987 | A |
4678422 | York | Jul 1987 | A |
4701038 | Neefe | Oct 1987 | A |
4715858 | Lindstrom | Dec 1987 | A |
4767647 | Bree | Aug 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4799784 | Safir | Jan 1989 | A |
4799931 | Lindstrom | Jan 1989 | A |
4807623 | Lieberman | Feb 1989 | A |
4813955 | Achatz et al. | Mar 1989 | A |
4815690 | Shepherd | Mar 1989 | A |
4817789 | Paul | Apr 1989 | A |
4830855 | Stewart | May 1989 | A |
4842599 | Bronstein | Jun 1989 | A |
4842782 | Portney | Jun 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4863466 | Schlegel | Sep 1989 | A |
4881860 | Kanazawa | Nov 1989 | A |
4903695 | Warner et al. | Feb 1990 | A |
4907586 | Bille et al. | Mar 1990 | A |
4928815 | Paul | May 1990 | A |
4955904 | Atebara et al. | Sep 1990 | A |
4976732 | Vorosmarthy | Dec 1990 | A |
4994080 | Shepard | Feb 1991 | A |
5013319 | Davis | May 1991 | A |
5030230 | White | Jul 1991 | A |
5034166 | Rawlings et al. | Jul 1991 | A |
5041133 | Sayano et al. | Aug 1991 | A |
5055602 | Melpolder | Oct 1991 | A |
5087015 | Galley | Feb 1992 | A |
5090955 | Simon | Feb 1992 | A |
5092880 | Ohmi | Mar 1992 | A |
5094521 | Jolson et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5108427 | Majercik et al. | Apr 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5120121 | Rawlings et al. | Jun 1992 | A |
5137441 | Fogarty | Aug 1992 | A |
5147395 | Willis | Sep 1992 | A |
5171318 | Gibson et al. | Dec 1992 | A |
5185107 | Blake | Feb 1993 | A |
5188494 | Hatin | Feb 1993 | A |
5192316 | Ting | Mar 1993 | A |
5196026 | Barrett et al. | Mar 1993 | A |
5213749 | Huss et al. | May 1993 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5266241 | Parekh | Nov 1993 | A |
5269795 | Arnott | Dec 1993 | A |
5269812 | White | Dec 1993 | A |
5274404 | Michael | Dec 1993 | A |
5288436 | Liu et al. | Feb 1994 | A |
5290892 | Namdaran et al. | Mar 1994 | A |
5292514 | Capecchi et al. | Mar 1994 | A |
5300116 | Chirila et al. | Apr 1994 | A |
5312330 | Klopotek | May 1994 | A |
5314439 | Sugita | May 1994 | A |
5314961 | Anton et al. | May 1994 | A |
5332802 | Kelman et al. | Jul 1994 | A |
5336261 | Barrett et al. | Aug 1994 | A |
5354331 | Schachar et al. | Oct 1994 | A |
5358520 | Patel | Oct 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5391201 | Barrett et al. | Feb 1995 | A |
5441511 | Hanna | Aug 1995 | A |
5474548 | Knopp et al. | Dec 1995 | A |
5507740 | O'Donnell, Jr. | Apr 1996 | A |
5507806 | Blake | Apr 1996 | A |
5547468 | Simon et al. | Apr 1996 | A |
D375245 | Irving | Nov 1996 | S |
5578080 | McDonald | Nov 1996 | A |
5603774 | LeBoeuf et al. | Feb 1997 | A |
5607437 | Simon et al. | Mar 1997 | A |
5624456 | Hellenkamp | Apr 1997 | A |
5627613 | Kaneko | May 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5628795 | Langerman | May 1997 | A |
5647865 | Swinger | Jul 1997 | A |
5652638 | Roffman et al. | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5674284 | Chang et al. | Oct 1997 | A |
5693268 | Widman et al. | Dec 1997 | A |
5697923 | Poler | Dec 1997 | A |
5702440 | Portney | Dec 1997 | A |
5708049 | Katagiri et al. | Jan 1998 | A |
5713957 | Steele et al. | Feb 1998 | A |
5722971 | Peyman | Mar 1998 | A |
5725575 | O'Donnell, Jr. | Mar 1998 | A |
5746558 | Nygren et al. | May 1998 | A |
5752967 | Kritzinger et al. | May 1998 | A |
5757458 | Miller et al. | May 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5774202 | Abraham et al. | Jun 1998 | A |
5786883 | Miller et al. | Jul 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
5837156 | Cumming | Nov 1998 | A |
5843105 | Mathis et al. | Dec 1998 | A |
5864128 | Plesko | Jan 1999 | A |
5870167 | Knopp et al. | Feb 1999 | A |
5876442 | Lipshitz et al. | Mar 1999 | A |
5895610 | Chang et al. | Apr 1999 | A |
5905561 | Lee et al. | May 1999 | A |
5910537 | Feingold et al. | Jun 1999 | A |
5913898 | Feingold et al. | Jun 1999 | A |
5919185 | Peyman | Jul 1999 | A |
5925294 | Shibuya | Jul 1999 | A |
5964748 | Peyman | Oct 1999 | A |
5964776 | Peyman | Oct 1999 | A |
5965330 | Evans et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
6017121 | Chateau et al. | Jan 2000 | A |
6063073 | Peyman | May 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6106553 | Feingold et al. | Aug 2000 | A |
6110166 | Juhasz et al. | Aug 2000 | A |
6138307 | McDonald | Oct 2000 | A |
6152959 | Portney | Nov 2000 | A |
6164777 | Li et al. | Dec 2000 | A |
6171336 | Sawusch | Jan 2001 | B1 |
6178593 | Carlson | Jan 2001 | B1 |
6197019 | Peyman | Mar 2001 | B1 |
6201036 | Fedorov et al. | Mar 2001 | B1 |
6203538 | Peyman | Mar 2001 | B1 |
6210401 | Lai | Apr 2001 | B1 |
6217571 | Peyman | Apr 2001 | B1 |
6217596 | Farah | Apr 2001 | B1 |
6221067 | Peyman | Apr 2001 | B1 |
6228113 | Kaufman | May 2001 | B1 |
6228114 | Lee | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6264648 | Peyman | Jul 2001 | B1 |
6277146 | Peyman et al. | Aug 2001 | B1 |
6280470 | Peyman | Aug 2001 | B1 |
6280471 | Peyman et al. | Aug 2001 | B1 |
6302877 | Ruiz | Oct 2001 | B1 |
6304390 | Takanashi | Oct 2001 | B1 |
6308590 | Berto | Oct 2001 | B1 |
6335190 | Zhou et al. | Jan 2002 | B1 |
6361560 | Nigam | Mar 2002 | B1 |
6376153 | Uchikawa et al. | Apr 2002 | B2 |
6387379 | Goldberg et al. | May 2002 | B1 |
6391230 | Sarbadhikari | May 2002 | B1 |
6416179 | Lieberman et al. | Jul 2002 | B1 |
6423093 | Hicks et al. | Jul 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6436092 | Peyman | Aug 2002 | B1 |
6458141 | Peyman | Oct 2002 | B1 |
6461384 | Hoffmann et al. | Oct 2002 | B1 |
6469844 | Iwase et al. | Oct 2002 | B1 |
6480346 | Funakoshi | Nov 2002 | B2 |
6491637 | Foster et al. | Dec 2002 | B2 |
6497700 | LaHaye | Dec 2002 | B1 |
6515006 | Horn | Feb 2003 | B2 |
6533416 | Fermigier et al. | Mar 2003 | B1 |
6551307 | Peyman | Apr 2003 | B2 |
6554424 | Miller et al. | Apr 2003 | B1 |
6554860 | Hoffmann et al. | Apr 2003 | B2 |
6555103 | Leukel et al. | Apr 2003 | B2 |
6575573 | Lai et al. | Jun 2003 | B2 |
6581993 | Nigam | Jun 2003 | B2 |
6588902 | Isogai | Jul 2003 | B2 |
6589280 | Koziol | Jul 2003 | B1 |
6607527 | Ruiz et al. | Aug 2003 | B1 |
6613088 | Babizhayev | Sep 2003 | B1 |
6638304 | Azar | Oct 2003 | B2 |
6649722 | Rosenzweig et al. | Nov 2003 | B2 |
6655804 | Streibig | Dec 2003 | B2 |
6692126 | Xie et al. | Feb 2004 | B1 |
6702807 | Peyman | Mar 2004 | B2 |
6726322 | Andino et al. | Apr 2004 | B2 |
6740116 | Morcher | May 2004 | B2 |
6755858 | White | Jun 2004 | B1 |
6786926 | Peyman | Sep 2004 | B2 |
6811256 | Becherer et al. | Nov 2004 | B1 |
6855163 | Peyman | Feb 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6899424 | Miller et al. | May 2005 | B2 |
6949093 | Peyman | Sep 2005 | B1 |
6951556 | Epstein | Oct 2005 | B2 |
6966648 | Miller et al. | Nov 2005 | B2 |
6989008 | Peyman | Jan 2006 | B2 |
6997428 | Andino et al. | Feb 2006 | B1 |
7001374 | Peyman | Feb 2006 | B2 |
7008447 | Koziol | Mar 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7099057 | Parker et al. | Aug 2006 | B2 |
7276080 | Murakami et al. | Oct 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7364674 | Hoover | Apr 2008 | B1 |
7399811 | Mentak et al. | Jul 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7446157 | Mentak et al. | Nov 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455691 | Feingold et al. | Nov 2008 | B2 |
7462193 | Nagamoto | Dec 2008 | B2 |
7477452 | Tsuruma | Jan 2009 | B2 |
7491350 | Silvestrini | Jan 2009 | B2 |
7497866 | Perez | Mar 2009 | B2 |
7628810 | Christie et al. | Dec 2009 | B2 |
7641337 | Altmann | Jan 2010 | B2 |
7645299 | Koziol | Jan 2010 | B2 |
7745555 | Mentak et al. | Jun 2010 | B2 |
7780290 | Zhao | Aug 2010 | B2 |
7842367 | Mentak | Nov 2010 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
D645337 | Hsu et al. | Sep 2011 | S |
8043371 | Paul et al. | Oct 2011 | B2 |
8048972 | Mentak et al. | Nov 2011 | B2 |
8079706 | Silvestrini et al. | Dec 2011 | B2 |
D656526 | Christie et al. | Mar 2012 | S |
8157374 | Bandhauer et al. | Apr 2012 | B2 |
8241354 | Hong et al. | Aug 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
D681086 | Christie et al. | Apr 2013 | S |
8420753 | Mentak et al. | Apr 2013 | B2 |
8439498 | Zhao et al. | May 2013 | B2 |
8460374 | Christie et al. | Jun 2013 | B2 |
8562131 | Zhao | Oct 2013 | B2 |
8604098 | Boydston et al. | Dec 2013 | B2 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8747466 | Weeber et al. | Jun 2014 | B2 |
8752958 | Miller et al. | Jun 2014 | B2 |
8633292 | Hu et al. | Jul 2014 | B2 |
8858624 | Christie et al. | Oct 2014 | B2 |
8864824 | Silvestrini et al. | Oct 2014 | B2 |
8955968 | Zalevsky et al. | Feb 2015 | B2 |
9005281 | Christie et al. | Apr 2015 | B2 |
9138142 | Christie et al. | Sep 2015 | B2 |
9204962 | Silvestrini | Dec 2015 | B2 |
9427311 | Christie et al. | Aug 2016 | B2 |
9427922 | Reboul et al. | Aug 2016 | B2 |
9492272 | Christie et al. | Nov 2016 | B2 |
9545303 | Vilupuru et al. | Jan 2017 | B2 |
9573328 | Reboul et al. | Feb 2017 | B2 |
9603704 | Silvestrini | Mar 2017 | B2 |
9744077 | Zicker et al. | Aug 2017 | B2 |
9757227 | Kushlin et al. | Sep 2017 | B2 |
9844919 | Reboul et al. | Dec 2017 | B2 |
9848979 | Vilupuru et al. | Dec 2017 | B2 |
9943403 | Webb et al. | Apr 2018 | B2 |
9987127 | Bogaert et al. | Jun 2018 | B2 |
10183453 | Reboul et al. | Jan 2019 | B2 |
10342656 | Vilupuru et al. | Jul 2019 | B2 |
10350058 | Silvestrini | Jul 2019 | B2 |
10426600 | Coleman et al. | Oct 2019 | B2 |
10449036 | Christie et al. | Oct 2019 | B2 |
10548717 | Webb et al. | Feb 2020 | B2 |
10583619 | Reboul et al. | Mar 2020 | B2 |
10687935 | Webb et al. | Jun 2020 | B2 |
20010027314 | Peyman | Oct 2001 | A1 |
20010034516 | Peyman | Oct 2001 | A1 |
20010050750 | Breger | Dec 2001 | A1 |
20020010510 | Silverstrini | Jan 2002 | A1 |
20020082288 | Horn | Jun 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20020128710 | Eggleston | Sep 2002 | A1 |
20020167640 | Francis et al. | Nov 2002 | A1 |
20020196409 | Jani | Dec 2002 | A1 |
20030014042 | Juhasz et al. | Jan 2003 | A1 |
20030060880 | Feingold | Mar 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030135272 | Brady et al. | Jul 2003 | A1 |
20030149480 | Shadduck | Aug 2003 | A1 |
20030204258 | Graham et al. | Oct 2003 | A1 |
20030216763 | Patel | Nov 2003 | A1 |
20040019379 | Glick et al. | Jan 2004 | A1 |
20040056371 | Liao et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040106929 | Masket | Jun 2004 | A1 |
20040140578 | Kelly et al. | Jul 2004 | A1 |
20050027355 | Murakami et al. | Feb 2005 | A1 |
20050046794 | Silvestrini et al. | Mar 2005 | A1 |
20050056954 | Devlin | Mar 2005 | A1 |
20050090895 | Peyman | Apr 2005 | A1 |
20050124983 | Frey et al. | Jun 2005 | A1 |
20050134793 | Roffman | Jun 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050143751 | Makker et al. | Jun 2005 | A1 |
20050182488 | Peyman | Aug 2005 | A1 |
20050187621 | Brady | Aug 2005 | A1 |
20050288784 | Peyman | Dec 2005 | A1 |
20060064077 | Peyman | Mar 2006 | A1 |
20060079959 | Christie et al. | Apr 2006 | A1 |
20060113054 | Silvestrini | Jun 2006 | A1 |
20060135477 | Haitjema et al. | Jun 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060232665 | Schowengerdt et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060235514 | Silvestrini | Oct 2006 | A1 |
20060241751 | Marmo et al. | Oct 2006 | A1 |
20060247659 | Moeller et al. | Nov 2006 | A1 |
20060265058 | Silvestrini | Nov 2006 | A1 |
20060268226 | Christie et al. | Nov 2006 | A1 |
20060268227 | Christie et al. | Nov 2006 | A1 |
20060268228 | Christie et al. | Nov 2006 | A1 |
20060268229 | Silvestrini et al. | Nov 2006 | A1 |
20060270946 | Silvestrini et al. | Nov 2006 | A1 |
20060271026 | Silvestrini et al. | Nov 2006 | A1 |
20060271178 | Christie et al. | Nov 2006 | A1 |
20060271179 | Christie et al. | Nov 2006 | A1 |
20060271180 | Christie et al. | Nov 2006 | A1 |
20060271181 | Christie et al. | Nov 2006 | A1 |
20060271182 | Christie et al. | Nov 2006 | A1 |
20060271183 | Christie et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060271185 | Silvestrini | Nov 2006 | A1 |
20060274264 | Christie et al. | Dec 2006 | A1 |
20060274265 | Christie et al. | Dec 2006 | A1 |
20070032866 | Portney | Feb 2007 | A1 |
20070091472 | Alkemper et al. | Apr 2007 | A1 |
20070092592 | Chiang | Apr 2007 | A1 |
20070129797 | Lang et al. | Jun 2007 | A1 |
20070225691 | Silvestrini et al. | Sep 2007 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080077238 | Deacon et al. | Mar 2008 | A1 |
20080100921 | Nishikawa | May 2008 | A1 |
20080151183 | Altmann | Jun 2008 | A1 |
20080208335 | Blum et al. | Aug 2008 | A1 |
20080212030 | Bentley et al. | Sep 2008 | A1 |
20080220214 | Uozu et al. | Sep 2008 | A1 |
20080221674 | Blum et al. | Sep 2008 | A1 |
20080255663 | Akpek et al. | Oct 2008 | A1 |
20080269884 | Vannoy | Oct 2008 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20090012505 | Chernyak | Jan 2009 | A1 |
20090021692 | Miller et al. | Jan 2009 | A1 |
20090287306 | Smith et al. | Jan 2009 | A1 |
20090036880 | Bischoff et al. | Feb 2009 | A1 |
20090048608 | Boukhny et al. | Feb 2009 | A1 |
20090059168 | Miller et al. | Mar 2009 | A1 |
20090069817 | Peyman | Mar 2009 | A1 |
20090164008 | Hong et al. | Jun 2009 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090187242 | Weeber et al. | Jul 2009 | A1 |
20090204207 | Blum et al. | Aug 2009 | A1 |
20090213326 | Zhao | Aug 2009 | A1 |
20090222086 | Lui et al. | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090279048 | Hong et al. | Nov 2009 | A1 |
20090306773 | Silvestrini et al. | Dec 2009 | A1 |
20090323020 | Zhao et al. | Dec 2009 | A1 |
20100016961 | Hong et al. | Jan 2010 | A1 |
20100016965 | Hong et al. | Jan 2010 | A1 |
20100082100 | Mikawa | Apr 2010 | A1 |
20100127412 | Lake | May 2010 | A1 |
20100149618 | Sprague | Jun 2010 | A1 |
20100208199 | Levis et al. | Aug 2010 | A1 |
20100225014 | Bille | Sep 2010 | A1 |
20100312336 | Hong et al. | Dec 2010 | A1 |
20110037184 | Shoji et al. | Feb 2011 | A1 |
20110040376 | Christie et al. | Feb 2011 | A1 |
20110051080 | Bandhauer et al. | Mar 2011 | A1 |
20110125261 | Portney | May 2011 | A1 |
20110166652 | Bogaert et al. | Jul 2011 | A1 |
20110172675 | Danta et al. | Jul 2011 | A1 |
20110245919 | Pettit | Oct 2011 | A1 |
20110251685 | Chu | Oct 2011 | A1 |
20110292340 | Shimizu et al. | Dec 2011 | A1 |
20120203239 | Vukich et al. | Aug 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120309761 | Chow et al. | Dec 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20130053953 | Silvestrini | Feb 2013 | A1 |
20130131795 | Miller et al. | May 2013 | A1 |
20130147072 | Bothe et al. | Jun 2013 | A1 |
20130238091 | Danta et al. | Sep 2013 | A1 |
20130289543 | Mordaunt | Oct 2013 | A1 |
20140121767 | Simpson | May 2014 | A1 |
20140131905 | Webb | May 2014 | A1 |
20140200666 | Phillips | Jul 2014 | A1 |
20140336625 | Fernandez | Nov 2014 | A1 |
20140343541 | Scott et al. | Nov 2014 | A1 |
20140379078 | Trindade | Dec 2014 | A1 |
20150025627 | Christie et al. | Jan 2015 | A1 |
20150046094 | Chaudhary et al. | Feb 2015 | A1 |
20150073549 | Webb et al. | Mar 2015 | A1 |
20150177422 | Liu et al. | Jun 2015 | A1 |
20150183173 | Linhardt et al. | Jul 2015 | A1 |
20150250583 | Rosen et al. | Sep 2015 | A1 |
20150366658 | Christie et al. | Dec 2015 | A1 |
20160100938 | Bogaert et al. | Apr 2016 | A1 |
20160135947 | Webb et al. | May 2016 | A1 |
20160297107 | Shim et al. | Oct 2016 | A1 |
20170049560 | Cherne | Feb 2017 | A1 |
20170143477 | Christie et al. | May 2017 | A1 |
20180125639 | Vilupuru et al. | May 2018 | A1 |
20180133990 | Reboul et al. | May 2018 | A1 |
20180296322 | Webb et al. | Oct 2018 | A1 |
20180338826 | Link et al. | Nov 2018 | A1 |
20190076241 | Alarcon Heredia et al. | Mar 2019 | A1 |
20190193350 | Gu et al. | Jun 2019 | A1 |
20190269499 | Ellis | Sep 2019 | A1 |
20200000576 | Christie et al. | Jan 2020 | A1 |
20200179105 | Waterhouse et al. | Jun 2020 | A1 |
Number | Date | Country |
---|---|---|
2004201751 | May 2004 | AU |
1734305 | Feb 2006 | CN |
1875895 | Dec 2006 | CN |
100368846 | Feb 2008 | CN |
101322663 | Dec 2008 | CN |
101341426 | Jul 2012 | CN |
203647535 | Jun 2014 | CN |
2727410 | Dec 1978 | DE |
4134320 | Apr 1992 | DE |
0165652 | Dec 1985 | EP |
0443094 | Aug 1991 | EP |
1173790 | Jan 2002 | EP |
1674049 | Jun 2006 | EP |
1548489 | Aug 2006 | EP |
2111822 | Oct 2009 | EP |
2319457 | May 2011 | EP |
2243052 | Sep 2011 | EP |
2365379 | Sep 2011 | EP |
2455799 | May 2012 | EP |
2823789 | Jan 2015 | EP |
2364457 | Aug 2015 | EP |
2993514 | Mar 2016 | EP |
2349150 | Jul 2016 | EP |
2620687 | Mar 1989 | FR |
2649605 | Jan 1991 | FR |
1276003 | Jun 1972 | GB |
2507465 | May 2014 | GB |
62-167343 | Jul 1987 | JP |
64-002644 | Jan 1989 | JP |
H01-195852 | Aug 1989 | JP |
H02-7954 | Jan 1990 | JP |
04-158859 | Jun 1992 | JP |
06-509731 | Mar 1993 | JP |
H05-65340 | Sep 1993 | JP |
06-502782 | Mar 1994 | JP |
H07-067896 | Mar 1995 | JP |
07-265340 | Oct 1995 | JP |
08-103457 | Apr 1996 | JP |
H09-502542 | Mar 1997 | JP |
11-503657 | Aug 1997 | JP |
07-178125 | Jul 1998 | JP |
2000-047145 | Feb 2000 | JP |
2002-537895 | Nov 2002 | JP |
2003-502109 | Jan 2003 | JP |
2004-510199 | Apr 2004 | JP |
2004-538034 | Dec 2004 | JP |
2005-533576 | Nov 2005 | JP |
2007-516794 | Jun 2007 | JP |
2007-523720 | Aug 2007 | JP |
2008-506710 | Mar 2008 | JP |
S59-54527 | May 2008 | JP |
10-0335722 | May 2002 | KR |
2138837 | Sep 1999 | RU |
110978 | Mar 2011 | RU |
2456968 | Jul 2012 | RU |
2457812 | Aug 2012 | RU |
2459598 | Aug 2012 | RU |
2493801 | Sep 2013 | RU |
134049 | Nov 2013 | RU |
134784 | Nov 2013 | RU |
2500368 | Dec 2013 | RU |
2511081 | Apr 2014 | RU |
2517488 | May 2014 | RU |
1380743 | Mar 1988 | SU |
201103518 | Feb 2011 | TW |
WO 8705797 | Oct 1987 | WO |
WO 9503747 | Feb 1995 | WO |
WO 9508135 | Mar 1995 | WO |
WO 9635397 | Nov 1996 | WO |
WO 9848715 | Nov 1998 | WO |
WO 00025704 | May 2000 | WO |
WO 00038594 | Jul 2000 | WO |
WO 0051682 | Sep 2000 | WO |
WO 0052516 | Sep 2000 | WO |
WO 0070388 | Nov 2000 | WO |
WO 2001010641 | Feb 2001 | WO |
WO 0115779 | Mar 2001 | WO |
WO 0117460 | Mar 2001 | WO |
WO 0119364 | Mar 2001 | WO |
WO 01082815 | Nov 2001 | WO |
WO 02076320 | Oct 2002 | WO |
WO 02102241 | Dec 2002 | WO |
WO 03020177 | Mar 2003 | WO |
WO 03022168 | Mar 2003 | WO |
WO 03061518 | Jul 2003 | WO |
WO 2004014969 | Feb 2004 | WO |
WO 2004034917 | Apr 2004 | WO |
WO 2004105588 | Dec 2004 | WO |
WO 2004113959 | Dec 2004 | WO |
WO 2005082265 | Sep 2005 | WO |
WO 2006020638 | Feb 2006 | WO |
WO 2006047534 | May 2006 | WO |
WO 2006060380 | Jun 2006 | WO |
WO 2006069012 | Jun 2006 | WO |
WO 2006113377 | Oct 2006 | WO |
WO 2006113411 | Oct 2006 | WO |
WO 2006113563 | Oct 2006 | WO |
WO 2006113564 | Oct 2006 | WO |
WO 2007057734 | Oct 2007 | WO |
WO 2007133384 | Nov 2007 | WO |
WO 2007142981 | Dec 2007 | WO |
WO 2008036671 | Mar 2008 | WO |
WO 2008102096 | Aug 2008 | WO |
WO 2009050511 | Apr 2009 | WO |
WO 2009122409 | Oct 2009 | WO |
WO 2009140080 | Nov 2009 | WO |
WO 2009149060 | Dec 2009 | WO |
WO 2010002215 | Jan 2010 | WO |
WO 2010059214 | May 2010 | WO |
WO 2010118469 | Oct 2010 | WO |
WO 2011020074 | Feb 2011 | WO |
WO 2011020078 | Feb 2011 | WO |
WO 2011047076 | Apr 2011 | WO |
WO 2011069059 | Jun 2011 | WO |
WO 2011088107 | Jul 2011 | WO |
WO 2012170066 | Dec 2012 | WO |
WO 2011030509 | Feb 2013 | WO |
WO 2013019871 | Feb 2013 | WO |
WO 2013082545 | Jun 2013 | WO |
WO 2013101793 | Jul 2013 | WO |
WO 2013112589 | Aug 2013 | WO |
WO 2013123265 | Aug 2013 | WO |
WO 2014054946 | Apr 2014 | WO |
WO 2014074610 | May 2014 | WO |
WO 2014158653 | Oct 2014 | WO |
WO 2014164056 | Oct 2014 | WO |
WO 2014195059 | Dec 2014 | WO |
WO 2015021323 | Feb 2015 | WO |
WO 2015069927 | May 2015 | WO |
WO 2015073718 | May 2015 | WO |
WO 2015078271 | Jun 2015 | WO |
WO 2015086611 | Jun 2015 | WO |
WO 2016081493 | May 2016 | WO |
WO 2015108156 | Mar 2017 | WO |
WO 2017062316 | Apr 2017 | WO |
WO 2017091520 | Jun 2017 | WO |
WO 2019010178 | Jan 2019 | WO |
Entry |
---|
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015). |
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, in 13 pages. |
International Search Report and Written Opinion for PCT/US2016/055207 dated Jan. 18, 2017 in 15 pages. |
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596. |
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376. |
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-518. |
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743. |
Number | Date | Country | |
---|---|---|---|
20200337831 A1 | Oct 2020 | US |
Number | Date | Country | |
---|---|---|---|
62237429 | Oct 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15765611 | US | |
Child | 15931289 | US |